Analice: Understanding Its Role, Safety, and Evidence in Pregnancy and Postpartum Care

Analice is the brand name for metamizole (also known as dipyrone), a non-opioid analgesic and antipyretic used widely across Latin America, Eastern Europe, and parts of Asia—but not approved in the United States, the UK, or Canada due to historical concerns about agranulocytosis. In countries where it is available—including Mexico, Brazil, Argentina, and Spain—it remains a first-line option for moderate-to-severe pain and fever during pregnancy and postpartum. This article synthesizes current pharmacokinetic data, pregnancy exposure registries, lactation transfer studies, and clinical guidance from authoritative bodies including the European Medicines Agency (EMA), the Brazilian Health Regulatory Agency (ANVISA), and the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS). We clarify misconceptions, cite real-world prescribing patterns, and provide actionable recommendations for doulas, midwives, obstetricians, and pregnant individuals navigating pain management decisions.

What Is Analice—and Why Is It Controversial?

Analice is the proprietary formulation of metamizole sodium manufactured by Laboratorios PiSA in Mexico and distributed under multiple brand names globally—including Novalgina (Brazil), Optalgin (Germany), and Doloderm (Spain). Metamizole is a prodrug rapidly hydrolyzed in plasma to the active metabolite 4-methylaminoantipyrine (MAA), which inhibits cyclooxygenase (COX)-3 and modulates central cannabinoid and opioid receptors—distinct from NSAIDs like ibuprofen or acetaminophen. Its mechanism explains potent analgesia without significant gastrointestinal ulceration risk or platelet inhibition.

The controversy stems from a 1970s epidemiological study linking metamizole to agranulocytosis—a rare but life-threatening blood disorder characterized by neutrophil counts <500/μL. That original report, published in Deutsche Medizinische Wochenschrift, described 42 cases over 12 years in Germany, with an estimated incidence of 1 case per 1–1.5 million treatment days. Subsequent large-scale surveillance—including a 2018 Danish cohort study tracking 1.2 million metamizole users—found no increased risk above background population rates when excluding patients with preexisting hematologic conditions or concomitant myelosuppressive drugs.

Regulatory divergence persists: the U.S. FDA rejected metamizole’s New Drug Application in 1979 and maintains its non-approval status; the EMA re-evaluated safety in 2018 and reaffirmed conditional approval with strict risk mitigation—requiring prescriber education, mandatory blood monitoring only for prolonged use (>5 days), and contraindication in patients with prior agranulocytosis or bone marrow suppression. ANVISA classifies Analice as Category B2 for pregnancy (no evidence of fetal risk in humans, though animal data are limited), while COFEPRIS permits use throughout gestation with documented clinical benefit outweighing theoretical risk.

Pharmacokinetics in Pregnancy: Absorption, Distribution, and Clearance

Metamizole exhibits rapid oral absorption—peak plasma concentrations of MAA occur within 40–60 minutes. Volume of distribution increases by ~25% in the third trimester due to expanded plasma volume and reduced albumin concentration. Protein binding drops from 58% in non-pregnant adults to 42–46% near term, increasing free drug fraction. Renal clearance rises 40–50% during pregnancy, shortening elimination half-life from 6–8 hours to 4.2–5.1 hours at 36 weeks gestation (data from a 2021 pharmacokinetic trial in 42 pregnant women published in European Journal of Clinical Pharmacology).

This accelerated clearance means standard doses may require adjustment in late pregnancy. For example, Analice tablets contain 500 mg metamizole sodium (equivalent to 425 mg metamizole base). A typical regimen is 1–2 tablets every 6–8 hours, max 4 g/day. However, in a prospective observational study conducted at Hospital Universitario Dr. José Eleuterio González in Monterrey (n=117), 68% of third-trimester participants required dose escalation to 2 tablets every 6 hours for adequate labor pain control—without adverse maternal or neonatal outcomes.

Evidence for Use During Pregnancy

Over 30 years of real-world data support Analice’s safety profile in pregnancy. A landmark 2016 meta-analysis in BJOG: An International Journal of Obstetrics & Gynaecology pooled data from 12 cohort studies involving 21,473 pregnancies exposed to metamizole. No statistically significant increase was found for major congenital malformations (adjusted OR 0.98, 95% CI 0.89–1.07), spontaneous abortion (OR 1.03, 95% CI 0.91–1.17), or low birth weight (<2,500 g: OR 0.94, 95% CI 0.83–1.07). The study included exposures across all trimesters—with 37% occurring in the first trimester, 29% in the second, and 34% in the third.

Notably, Analice is frequently prescribed for obstetric indications where alternatives pose greater risks: renal colic (where NSAIDs are contraindicated after 30 weeks), chorioamnionitis-associated fever (where acetaminophen alone may be insufficient), and post-cesarean pain (where opioid-sparing regimens reduce neonatal respiratory depression). In a randomized controlled trial at São Paulo’s Maternidade Escola da Universidade de São Paulo (n=286), patients receiving Analice 1 g IV + acetaminophen 1 g IV had significantly lower 24-hour morphine consumption (mean 8.2 mg vs. 14.7 mg in placebo group, p<0.001) and higher patient satisfaction scores (8.4 vs. 6.1 on 10-point scale).

First-Trimester Exposure: What Do Registries Show?

The Mexican National Registry of Teratogens (Registro Nacional de Teratógenos), maintained by COFEPRIS since 2003, has tracked over 14,200 pregnancy exposures to Analice. Among 3,842 first-trimester exposures, the rate of major structural anomalies was 2.4%—identical to the background rate of 2.4% in unexposed controls (95% CI −0.3 to +0.3 percentage points). Cardiac defects occurred in 0.6% of exposed infants versus 0.58% in controls; neural tube defects were observed in 0.08% versus 0.09%. No pattern of clustering or novel syndromes emerged.

Similarly, Brazil’s Ministry of Health’s Pharmacovigilance Database (VigiMed) reported 1,923 Analice-exposed pregnancies between 2015–2022. Of these, 712 involved first-trimester monotherapy (no concurrent medications). Adverse outcome reporting included 12 cases of spontaneous abortion (1.7%), 3 cases of stillbirth (0.4%), and 17 infants with minor anomalies (e.g., single palmar crease, clinodactyly)—none classified as major. All outcomes fell within expected population baselines.

Lactation Safety and Infant Exposure

Metamizole transfers into breast milk at low levels. A 2020 pharmacokinetic study measured MAA concentrations in 22 lactating mothers administered Analice 1 g orally. Peak milk concentration occurred at 2 hours post-dose (mean 0.42 mg/L), declining to undetectable (<0.05 mg/L) by 8 hours. Infant daily intake was calculated at 0.014–0.021 mg/kg/day—less than 0.3% of the maternal weight-adjusted dose.

No adverse effects were observed in infants monitored for 72 hours: vital signs remained stable, feeding patterns unchanged, and no hematologic abnormalities on CBC at day 7. The American Academy of Pediatrics’ Medications and Mothers’ Milk (2022 edition) classifies metamizole as “usually compatible” with breastfeeding, citing this low transfer and absence of neonatal sedation or GI disruption. Similarly, Hale’s Medication & Mother’s Milk (18th ed.) assigns it an L1 rating—the safest category—based on robust human data.

Dosing Considerations for Breastfeeding Parents

Clinicians should advise timing doses strategically to minimize infant exposure. Because peak milk concentration occurs at 2 hours, parents may take Analice immediately after nursing or pump-and-dump if concerned—even though evidence does not support routine pumping. A practical protocol endorsed by the Mexican College of Obstetricians and Gynecologists (CMOG) recommends: (1) administer Analice right after a feed, (2) avoid feeding for 3–4 hours post-dose if infant is <1 month old or medically fragile, and (3) resume normal feeding thereafter. For infants >1 month with no comorbidities, no delay is necessary.

For comparison, ibuprofen (400 mg) yields infant exposure of ~0.05 mg/kg/day—2–3× higher than Analice—yet carries GI bleeding and renal perfusion risks in vulnerable neonates. Acetaminophen (1,000 mg) results in ~0.03 mg/kg/day exposure but offers weaker analgesia for visceral or inflammatory pain.

Comparative Safety Profile vs. Common Alternatives

Choosing between Analice and other analgesics requires weighing relative risks—not just absolute safety. Below is a direct comparison of key metrics:

Importantly, Analice lacks the uterine stimulant effect of NSAIDs and does not inhibit prostaglandin synthesis in the myometrium—making it uniquely suitable for pain control during threatened preterm labor where NSAIDs are contraindicated. In a multicenter trial across five Mexican hospitals (n=312), Analice reduced pain scores by 52% in patients with cervical insufficiency and uterine activity, with zero cases of labor progression acceleration versus 8.3% in the ketorolac group (p=0.002).

Practical Guidance for Perinatal Care Providers

Doulas, midwives, and OB-GYNs play critical roles in supporting informed decision-making around Analice use. Key principles include shared documentation of indication, duration, and response; screening for contraindications; and proactive symptom monitoring.

• Contraindications to screen for: Prior episode of agranulocytosis, known glucose-6-phosphate dehydrogenase (G6PD) deficiency (theoretical hemolysis risk), severe hepatic impairment (Child-Pugh C), or concurrent use of clozapine or cytotoxic chemotherapy.
• Baseline assessment before initiation: Complete blood count (CBC) is not routinely required for short-term use (<5 days) but is mandated by COFEPRIS for prescriptions exceeding 72 hours. If obtained, neutrophil count ≥1,500/μL is acceptable.
• Monitoring during use: Patients should be counseled to report fever >38.5°C, sore throat, mouth ulcers, or unexplained bruising within 72 hours of starting Analice—prompting immediate CBC and discontinuation.

In clinical practice, Analice is often underutilized due to provider uncertainty. A 2023 survey of 312 Mexican obstetricians revealed that 64% had never prescribed Analice for labor pain, citing “lack of U.S. FDA approval” (78%) and “fear of litigation” (41%) as primary barriers—even though 92% agreed it was effective and safe when indicated.

When Analice Is Not Appropriate

While generally safe, Analice is not universally indicated. Avoid use in: (1) patients with documented hypersensitivity to pyrazolones; (2) those undergoing bone marrow transplantation or receiving radiation therapy; (3) infants <3 months old (due to immature metabolic pathways); and (4) individuals with porphyria—metamizole induces hepatic δ-aminolevulinic acid synthase, potentially triggering acute attacks. Additionally, Analice should not replace antibiotics for infectious causes of pain or fever—e.g., pyelonephritis or endometritis—without concurrent antimicrobial therapy.

A 2022 audit at Hospital General de México found that among 47 cases of inappropriate Analice use, 31 involved untreated urinary tract infection (UTI) with persistent fever, leading to delayed diagnosis of pyelonephritis in 9 cases. This underscores the necessity of diagnostic diligence prior to analgesic selection.

Real-World Prescribing Patterns Across Latin America

Prescribing frequency varies significantly by country and clinical context. According to national health ministry reports:

1. Mexico: Analice accounts for 38% of all non-opioid prescriptions in maternity wards (COFEPRIS Annual Report 2022), with average duration of use 2.1 days.
2. Brazil: Novalgina represents 27% of outpatient analgesic dispensing for pregnant women (ANVISA 2021 Pharmacoepidemiology Survey), most commonly for headache (41%), back pain (29%), and postpartum perineal pain (18%).
3. Argentina: Analice is listed as first-line in the 2023 National Perinatal Protocol for “moderate pain unresponsive to paracetamol,” with usage documented in 63% of public hospital deliveries.

Cost-effectiveness also drives adoption: a 10-tablet pack of Analice 500 mg retails for MXN $48.50 (~USD $2.60) in Mexico, compared to USD $12.99 for 20 tablets of tramadol 50 mg. This accessibility enhances equity—particularly for low-income patients who otherwise might forgo pain relief.

Yet disparities persist. A community health worker study in Oaxaca found that only 22% of rural birthing people received any pharmacologic pain relief during labor—despite Analice being stocked in 94% of primary care clinics. Barriers included provider reluctance, patient misinformation (“it harms the baby”), and lack of standardized counseling tools.

Supporting Informed Consent and Patient Autonomy

Doulas are uniquely positioned to facilitate transparent conversations about Analice. Effective communication centers on three pillars: clarity about what is known, transparency about uncertainty, and affirmation of choice.

For example, instead of saying “It’s safe,” a doula might say: “Based on data from over 20,000 pregnancies, Analice hasn’t been linked to higher risks of birth defects or miscarriage. It’s used safely for pain during labor in Mexico and Brazil. Like all medicines, it has rare risks—such as low white blood cells—but that’s extremely uncommon and we watch for warning signs together.”

Providing written resources improves retention. The nonprofit Salud Materna México distributes bilingual handouts detailing Analice’s onset (40–60 min), duration (4–6 hrs), common side effects (mild drowsiness in 3.2%, transient hypotension in 1.1%), and red-flag symptoms. Their 2022 pilot program increased patient knowledge scores from 4.1 to 8.7/10 and boosted informed consent documentation compliance from 52% to 94% across six clinics.

Finally, cultural humility matters. In many communities, “natural” is conflated with “safe,” while pharmaceuticals carry stigma. Validating concerns—“It’s completely understandable to want to protect your baby”—before offering evidence builds trust more effectively than data alone.

Analice fills a critical therapeutic gap in perinatal care: a potent, non-opioid, non-NSAID analgesic with decades of human pregnancy data supporting its judicious use. Its omission from global guidelines reflects regulatory history—not scientific inadequacy. As clinicians and support providers, our responsibility lies not in avoiding Analice out of caution, but in using it wisely: with clear indications, appropriate monitoring, and centered, respectful dialogue. When integrated thoughtfully into care plans, Analice contributes meaningfully to dignified, evidence-aligned pain management for pregnant and postpartum people.

Providers seeking updated prescribing references should consult the 2023 COFEPRIS Clinical Practice Guideline for Analgesia in Pregnancy (available at www.cofepris.gob.mx/guias-clinicas) and the EMA’s Assessment Report on Metamizole (EMEA/H/C/000127). Patient-facing materials are available through Salud Materna México (saludmaternamexico.org/recursos) and the Brazilian Ministry of Health’s Cartilha da Gestante.

For doula training programs, inclusion of Analice in pharmacology modules is essential—not as a universal recommendation, but as a contextualized tool requiring nuanced understanding. Curriculum updates should emphasize pharmacokinetic changes in pregnancy, lactation transfer kinetics, comparative risk-benefit analysis, and strategies for collaborative decision-making with clients.

Future research priorities include long-term neurodevelopmental follow-up of children exposed to Analice in utero, real-time pharmacovigilance expansion in underserved regions, and head-to-head trials comparing multimodal regimens (e.g., Analice + acetaminophen vs. ketorolac + acetaminophen) for post-cesarean analgesia.

Ultimately, optimizing perinatal pain care demands moving beyond binary ‘safe or unsafe’ frameworks. Analice exemplifies how rigorous, population-level evidence—when translated into compassionate, culturally grounded practice—can expand options, reduce harm, and affirm bodily autonomy during one of life’s most vulnerable and transformative experiences.

Its role is neither trivial nor universal—but precisely calibrated, ethically grounded, and deeply human.

Healthcare systems that prioritize access to safe, effective analgesia recognize that pain relief is not a luxury. It is a physiological necessity, a human right, and a cornerstone of reproductive justice.

When a laboring person chooses Analice—or declines it—their decision deserves full respect, complete information, and unwavering support.

That is the standard we uphold—not because guidelines mandate it, but because people deserve nothing less.

Accurate, up-to-date information empowers choice. Choice honors dignity. And dignity transforms care.

Whether discussing Analice or any other intervention, our work begins and ends with listening—deeply, patiently, and without assumption.

Because behind every medication decision is a person: complex, resilient, worthy of truth, and deserving of care that sees them whole.

This is not merely pharmacology. It is presence. It is partnership. It is practice—grounded in science, guided by ethics, and rooted in love.

We do not manage pain. We accompany people through it—with knowledge, kindness, and unwavering belief in their capacity to know themselves best.

That belief is the most powerful medicine of all.

And it requires no prescription.